Several brain complications of SARS-CoV-2 infection have been already reported including acute cerebrovascular disorders, encephalopathy, encephalitis, and Guillain-Barré syndromes \[[@CR1]\]. It has been moreover speculated that SARS-CoV-2 neurotropism could potentially cause a delayed outbreak with onset and progression of neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin \[[@CR2]\]. A recent systematic review and meta-analysis of other coronavirus infections confirms confusion, depressed mood, anxiety, impaired memory, or insomnia in 27.9 to 41.9% of patients in the acute illness, while in the post-illness stage, the prevalence of post-traumatic stress disorder was of 32.2%, and almost 15% for depression and anxiety disorders \[[@CR3]\], with also a clinical overlap with fibromyalgia and chronic fatigue syndrome \[[@CR4]\].

As previously shown for other SARS-CoV infections, a propagation mechanism has been proposed across the cribriform plate of the ethmoid bone, from the nose to the olfactory epithelium where ACE2 receptors are highly expressed \[[@CR5]\]. This viral neurotropism through the olfactory bulb could be especially responsible of the anosmia frequently reported in these patients \[[@CR5]\]. Accordingly, a cortical FLAIR-MRI hyperintensity was visually identified in the right gyrus rectus and olfactory bulb of a patient with SARS-CoV-2 anosmia \[[@CR6]\]. By trans-synaptic transfer, again already reported for other virus \[[@CR7]\], this propagation from the olfactory bulb could spread to other limbic structures, such as the amygdala, the hippocampus, and the cingulate cortex which are well known to be involved in cognition and emotion \[[@CR8]\] and pathologically in neurodegenerative and neuropsychiatric diseases \[[@CR2]\]. SARS-CoV-2 may also target deeper parts of the brain including the thalamus and the brainstem and then potentially contributes to the respiratory impairment \[[@CR7]\] and also to painful symptoms.

We report here the clinical case of two patients with confirmed diagnosis of SARS-CoV-2, which were explored by whole-body ^18^F-FDG PET in the post-illness stage to metabolically characterize residual lung abnormalities. Brain PET metabolism was statistically analyzed in comparison with healthy subjects at whole-brain voxel-based level (proportional scaling; *p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected; healthy subjects of same median age as the patient around a ± 10-year range), and findings were confronted to the hypothesis of the propagation of SARS-Co-2 from the olfactory bulb to other limbic structures and possibly the brainstem.

Case reports {#Sec1}
============

We first report the case of a 54-year-old man with a SARS-CoV-2 confirmed by nasopharyngeal swab. Type 2 diabetes, hypertension, and minor asthma were found in his past medical history. The pneumonia was complicated with a severe acute respiratory distress syndrome requiring 6 days of mechanical ventilation and 15 days of hospitalization in intensive care unit. The evolution was clinically favorable, with nevertheless the persistence of anosmia and ageusia during 4 additional weeks and delayed occurrence of memory complaints 8 weeks after the first pulmonary symptoms. A whole-body ^18^F-FDG PET was afterward performed, while the patients only complained of memory impairment, to evaluate the metabolic activity of persistent pulmonary CT condensations. No suspect lung hypermetabolism was found. The brain ^18^F-FDG PET exhibited hypometabolism of bilateral rectal gyrus prevailing on the right side, without evident abnormality on the attenuation correction CT scan. A whole-brain voxel-based SPM8 comparison, to a local database of 23 healthy subjects selected on the same median age as the patient (range of ± 10 years around the age of the patient; mean age, 54.4 years old; standard deviation, 6.7 years), confirms hypometabolism of the right olfactory/rectal gyrus, with interestingly no remote abnormalities to point toward another brain gateway (Fig. [1](#Fig1){ref-type="fig"}; *p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected; Table [1](#Tab1){ref-type="table"}).Fig. 1Brain ^18^F-FDG PET hypometabolism of the first patient. Bilateral hypometabolism of olfactory/rectal gyrus is visually identified (white arrow), and confirmed by whole-brain voxel-based SPM8 comparison, to healthy subjects (*p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected)Table 1Main ^18^F-FDG PET hypometabolic findings for each patient in comparison to healthy subjects (*p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected)ClusterClusterVoxelvoxelTalairach coordinatesLocalizationk*p* value*T* score*p* value*xyz*Case 12860.0235.97\< 0.0014.030.0− 27.0Right rectal gyrus (BA11)Case 23574\< 0.001\*6.92\< 0.001\*− 22.0− 37.0− 2.0Left hippocampus6.64\< 0.001\*− 18.0− 43.0− 3.0Left parahippocampal gyrus (BA19)5.39\< 0.001− 18.0− 16.0− 13.0Left parahippocampal gyrus (BA28)5.27\< 0.00120.0− 26.0− 9.0Right parahippocampal gyrus (BA28)4.70\< 0.001− 8.0− 50.04.0Left cerebellar anterior lobe4.58\< 0.001− 6.0− 6.0− 3.0Hypothalamus4.48\< 0.001− 6.0− 16.0− 1.0Left thalamus4.35\< 0.00118.03.0− 17.0Right parahippocampal gyrus (BA34)4.30\< 0.00124.05.0− 19.0Right uncus (BA28)4.29\< 0.00126.0− 37.0− 3.0Right hippocampus4.18\< 0.0016.020.0− 25.0Right rectal gyrus (BA11)4.13\< 0.0012.0− 32.0− 22.0Right cerebellar culmen6040.001\*5.87\< 0.001− 4.0− 31.0− 40.0Medulla3.79\< 0.00118.0− 34.0− 29.0Pons3.710.00112.0− 35.0− 40.0Right cerebellar tonsil5870.001\*5.29\< 0.001− 4.0− 12.037.0Left cingulate gyrus (BA24)3.91\< 0.001− 10.0− 43.033.0Left cingulate gyrus (BA31)3900.007\*5.08\< 0.00159.0− 1.013.0Right pre-central gyrus (BA6)4.91\< 0.00161.0− 23.014.0Right post-central gyrus (BA40)4.48\< 0.00163.0− 36.015.0Right superior temporal gyrus (BA22)The *k* value represents the number of voxels inside a particular cluster. *p* values are all presented as uncorrected for multiple comparisons. *p* values still significant at *p* \< 0.05 after correction for multiple comparisons using FWE method (family-wise error) are indicated with \*. Talairach coordinates are expressed in mm. *BA* Brodmann Area

We secondly report the case of a 62-year-old man with a SARS-CoV-2 pneumonia confirmed by nasopharyngeal swab. The patient had not significant antecedent. The pneumonia was complicated with moderate acute respiratory distress syndrome requiring 24-h hospitalization in intensive care unit and treatment by low-flow nasal oxygen. The patient never experienced anosmia or ageusia. The evolution was clinically favorable with nevertheless the occurrence, 7 days after the first pulmonary symptoms, of sensitive lower leg crushing sensation alternating in right/left toes, without any motor or sensory deficiency on clinical examination. The hypothesis of peripheral involvement is still in investigation. A whole-body ^18^F-FDG PET was afterwards performed, while the patients only complained of this painful syndrome, to evaluate the metabolic activity of persistent pulmonary CT condensations. No suspect lung hypermetabolism was found. The brain ^18^F-FDG PET exhibited extended bilateral marked hypometabolism especially involving olfactory/rectal gyrus, other limbic structures such as amygdala, hippocampus, parahippocampus and cingulate cortex, as well as the right pre-/post-central gyrus, the right superior temporal gyrus, bilateral thalamus, hypothalamus, cerebellum, pons and medulla. These hypometabolisms are found on a whole-brain voxel-based SPM8 comparison with a local database of 24 healthy subjects selected on the same median age as the patient (range of ± 10 years around the age of the patient; mean age, 62.2 years old; standard deviation, 7.0 years) (Fig. [2](#Fig2){ref-type="fig"}; *p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected; Table [1](#Tab1){ref-type="table"}). No abnormality was found on the attenuation correction CT scan.Fig. 2Brain ^18^F-FDG PET hypometabolism of the second patient. Bilateral hypometabolism of olfactory/rectal gyrus (white arrow), medial temporal lobe (white\*), and brainstem (white+) is visually identified, and confirmed by whole-brain voxel-based SPM8 comparison to healthy subjects (*p* voxel \< 0.001, *p*-cluster \< 0.05, uncorrected), also including the right pre-/post-central gyrus, the right superior temporal gyrus, bilateral thalamus, hypothalamus, and cerebellum

Discussion {#Sec2}
==========

These preliminary findings reinforce the hypotheses of SARS-CoV-2 neurotropism through the olfactory bulb in patients with or without anosmia, and the possible extension of this impairment to other limbic structures as well as to the pre-/post-central gyrus, the thalamus/hypothalamus, the cerebellum and the brainstem, with brain abnormalities persisting after the remission of the infectious phase. ^18^F-FDG PET hypometabolism could constitute a cerebral quantitative biomarker of this involvement \[[@CR9]\]. Post-viral cohort studies with longer follow-up are required to specify the exact relationship between such hypometabolisms and the possible persistent disorders, especially involving cognitive or emotion disturbances, residual respiratory symptoms, or painful complaints. More earlier brain PET studies could also investigate the possible transition between hyper- and hypo-metabolisms in these patients. These metabolic features could be also correlated to other brain PET biomarkers of neuroinflammation and infection, such as TSPO and CXCR4 expressions \[[@CR10]\], and also to the impact of anti-inflammatory therapeutics, to address the possible relationship with the hypothesized association to neuropsychiatric and neurodegenerative diseases of neuroinflammatory origin \[[@CR2]\].
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